Home »
Academic Articles »
C »
Protection of calves by a prefusion-stabilized bovine RSV F vaccine
Protection of calves by a prefusion-stabilized bovine RSV F vaccine
Baoshan Zhang
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Lei Chen
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Chiara Silacci
(Institute for Research in Biomedicine, Università della Svizzera italiana)
Michelle Thom
(The Pirbright Institute)
Jeffrey C. Boyington
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Aliaksandr Druz
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
M. Gordon Joyce
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Efrain Guzman
(The Pirbright Institute)
Wing- Pui Kong
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Yen-Ting Lai
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Guillaume B. E. Stewart-Jones
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Yaroslav Tsybovsky
(Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research)
Yongping Yang
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Tongqing Zhou
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Ulrich Baxa
(Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research)
John R. Mascola
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Davide Corti
(Institute for Research in Biomedicine, Università della Svizzera italiana)
Antonio Lanzavecchia
(Institute for Research in Biomedicine, Università della Svizzera italiana)
Geraldine Taylor
(The Pirbright Institute)
Peter D. Kwong
(Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)
Respiratory disease: A bovine model for respiratory syncytial virus vaccines Researchers have produced a vaccine that protects against bovine respiratory syncytial virus (bRSV) in calves, with implications for humans. An international team comprising Geraldine Taylor, The Pirbright Institute, UK, Davide Corti and Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland, and Peter Kwong, Vaccine Research Center, NIAID, NIH, United States, and their teams constructed the subunit vaccine from an engineered bRSVfusion (F) glycoprotein that protected challenged calves by generating a highly protective immune response. This approach allays some of the dangers of whole-virus vaccines. The results warrant further investigation, as current bRSV vaccines have significant downsides.Moreover, as the engineered bRSV F glycoprotein is structurally and reactively similar to the prefusion-stabilized human RSV (hRSV) F glycoprotein, the findings highlight potential benefits of similar vaccines in humans, as no licensed hRSV vaccine is currently available.
Baoshan Zhang, Lei Chen, Chiara Silacci, et al. (2017). "Protection of calves by a prefusion-stabilized bovine RSV F vaccine". npj Vaccines. https://doi.org/10.1038/s41541-017-0005-9